STOCK TITAN

Xeris Biopharma Holdings, Inc. - XERS STOCK NEWS

Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.

Xeris Biopharma Holdings, Inc. (Symbol: XERS) is a pioneering biopharmaceutical company committed to developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company's mission is to revolutionize patient care by creating ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices.

Xeris has successfully brought three groundbreaking products to market:

  • Gvoke: A ready-to-use liquid glucagon designed to treat severe hypoglycemia, providing a critical solution for diabetic patients.
  • Keveyis: The first FDA-approved therapy for primary periodic paralysis, offering relief for those suffering from this rare genetic disorder.
  • Recorlev: Approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome, addressing a previously unmet need in this patient population.

In addition to these commercial successes, Xeris continues to innovate with a robust pipeline of development programs. Utilizing its proprietary formulation technologies, XeriSol and XeriJect, the company aims to bring new therapies to market that ease the administration and increase the efficacy of injectable treatments.

Financially, Xeris Biopharma Holdings has shown significant growth and resilience in a competitive market. Their strategic partnerships and collaborations further bolster their developmental and commercial capabilities, ensuring a steady pipeline of innovative products aimed at improving patient outcomes.

Recent achievements and ongoing projects underline Xeris' commitment to enhancing the quality of life for millions of patients globally. Keep up with the latest updates and news about Xeris Biopharma Holdings, Inc. to stay informed about their ongoing advancements and performance in the biopharmaceutical industry.

Rhea-AI Summary
Xeris Biopharma Holdings, Inc. announces exchange agreements for convertible notes, providing financial flexibility and extending maturity date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
none
-
Rhea-AI Summary
Xeris Biopharma to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
conferences
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.58%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
-
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (XERS) to Host Q2 2023 Financial Results Conference Call and Webcast at 8:30am ET
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
conferences earnings
-
News
Rhea-AI Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced that it has shipped over one million units of Gvoke®, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes. This milestone comes in light of updated guidelines recognizing the importance of ready-to-use glucagon for people with diabetes at risk of severe hypoglycemia. The American Diabetes Association and others estimate that approximately 15 million people with diabetes are at increased risk of low blood sugar, emphasizing the need for products like Gvoke HypoPen®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.75%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
conferences earnings

FAQ

What is the current stock price of Xeris Biopharma Holdings (XERS)?

The current stock price of Xeris Biopharma Holdings (XERS) is $3.41 as of January 23, 2025.

What is the market cap of Xeris Biopharma Holdings (XERS)?

The market cap of Xeris Biopharma Holdings (XERS) is approximately 487.5M.

What does Xeris Biopharma Holdings, Inc. specialize in?

Xeris focuses on developing and commercializing innovative therapies in endocrinology, neurology, and gastroenterology.

What are the main products of Xeris Biopharma?

Xeris' main products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous hypercortisolemia in Cushing's Syndrome.

What is Gvoke used for?

Gvoke is a ready-to-use liquid glucagon designed to treat severe hypoglycemia in diabetic patients.

What makes Xeris' therapies unique?

Xeris' therapies are unique due to their ultra-low volume, ready-to-use formulations delivered through patient-friendly injectable devices.

What proprietary technologies does Xeris use?

Xeris uses proprietary formulation technologies such as XeriSol and XeriJect to enhance the administration and efficacy of injectable treatments.

How many products has Xeris successfully commercialized?

Xeris has three commercially available products: Gvoke, Keveyis, and Recorlev.

What is Keveyis used for?

Keveyis is the first FDA-approved therapy for primary periodic paralysis, a rare genetic disorder.

What is Recorlev approved to treat?

Recorlev is approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

What are XeriSol and XeriJect?

XeriSol and XeriJect are Xeris' proprietary formulation technologies used to develop advanced injectable therapies.

Where can I find the latest news about Xeris Biopharma Holdings?

You can find the latest news about Xeris Biopharma Holdings on their official website and stock market news platforms like StockTitan.
Xeris Biopharma Holdings, Inc.

Nasdaq:XERS

XERS Rankings

XERS Stock Data

487.50M
141.68M
3.92%
43.97%
6.38%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO